Efficacy of Transarterial Chemoembolization Targeting Portal Vein Tumor Thrombus in Patients with Hepatocellular Carcinoma

被引:5
作者
Tawada, Akinobu [1 ]
Chiba, Tetsuhiro [1 ]
Ooka, Yoshihiko [1 ]
Kanogawa, Naoya [1 ]
Motoyama, Tenyu [1 ]
Saito, Tomoko [1 ]
Ogasawara, Sadahisa [1 ]
Suzuki, Eiichiro [1 ]
Maruyama, Hitoshi [1 ]
Kanai, Fumihiko [1 ]
Yoshikawa, Masaharu [1 ]
Yokosuka, Osamu [1 ]
机构
[1] Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chiba 2608670, Japan
关键词
Hepatocellular carcinoma; transcatheter arterial chemoembolization; portal vein tumor thrombus; prognosis; survival; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; NATURAL-HISTORY; EMBOLIZATION; MANAGEMENT; CANCER; SAFETY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: We aimed to retrospectively examine the tolerability and efficacy of transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Patients and Methods: Adverse events were assessed using the Common Terminology Criteria for Adverse Events, version 4.0. The efficacy of TACE in parenchymal tumors (parenchymal response) and PVTT (PVTT response) was separately evaluated by dynamic computed tomography I to 2 months after TACE according to the Response Evaluation Criteria in Cancer of the Liver (RECICL). Patients with complete remission plus partial response in parenchymal tumors and PVTT were assessed as parenchymal response-positive and PVTT response-positive, respectively. Results: A total of 33 HCC patients with PVTT were analyzed. Grade 314 toxicities included elevated aspartate aminotransferase levels (69.7%), elevated alanine aminotransferase levels (54.5%), hyponatremia (6.1%), thrombocytopenia (6.1%), hyperbilirubinemia (3.0%), leukopenia (3.0%) and anemia (3.0%). All these findings returned to the pre-treatment levels within I month after TACE. The number of parenchymal response-positive/negative and PVTT response-positive/negative patients was 20113 and 13120, respectively. Kaplan-Meier analyses revealed that the cumulative survival rate was significantly higher in parenchymal response-positive (p=0.04) and PVTT response-positive (p<0.01) patients than in their negative counterparts. PVTT response was a favorable prognostic factor for overall survival in multivariate analysis (p=0.03). Conclusion: TACE was feasible in HCC patients with PVTT and could improve their survival by showing direct therapeutic effect against PVTT.
引用
收藏
页码:4231 / 4237
页数:7
相关论文
共 26 条
[1]   Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009) [J].
Arii, Shigeki ;
Sata, Michio ;
Sakamoto, Michiie ;
Shimada, Mitsuo ;
Kumada, Takashi ;
Shiina, Shuichiro ;
Yamashita, Tatsuya ;
Kokudo, Norihiro ;
Tanaka, Masatoshi ;
Takayama, Tadatoshi ;
Kudo, Masatoshi .
HEPATOLOGY RESEARCH, 2010, 40 (07) :667-685
[2]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[3]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[4]   Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses [J].
Choi, Gwang Hyeon ;
Shim, Ju Hyun ;
Kim, Min-Joo ;
Ryu, Min-Hee ;
Ryoo, Baek-Yeol ;
Kang, Yoon-Koo ;
Shin, Yong Moon ;
Kim, Kang Mo ;
Lim, Young-Suk ;
Lee, Han Chu .
RADIOLOGY, 2013, 269 (02) :602-610
[5]   Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival [J].
Chung, Goh Eun ;
Lee, Jeong-Hoon ;
Kim, Hwi Young ;
Hwang, Sang Youn ;
Kim, Joon Suk ;
Chung, Jin Wook ;
Yoon, Jung-Hwan ;
Lee, Hyo-Suk ;
Kim, Yoon Jun .
RADIOLOGY, 2011, 258 (02) :627-634
[6]   Hepatic tumors: Predisposing factors for complications of transcatheter oily chemoembolization [J].
Chung, JW ;
Park, JH ;
Han, JK ;
Choi, BI ;
Han, MC ;
Lee, HS ;
Kim, CY .
RADIOLOGY, 1996, 198 (01) :33-40
[7]   HEPATOCELLULAR-CARCINOMA AND PORTAL-VEIN INVASION - RESULTS OF TREATMENT WITH TRANSCATHETER OILY CHEMOEMBOLIZATION [J].
CHUNG, JW ;
PARK, JH ;
HAN, JK ;
CHOI, BI ;
HAN, MC .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1995, 165 (02) :315-321
[8]  
European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.jhep.2011.12.001, 10.1016/j.ejca.2011.12.021]
[9]   Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis [J].
Georgiades, CS ;
Hong, K ;
D'Angelo, M ;
Geschwind, JFH .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2005, 16 (12) :1653-1659
[10]   Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion [J].
Kim, Kang Mo ;
Kim, Jong Hoon ;
Park, Ik Soo ;
Ko, Gi-Young ;
Yoon, Hyun-Ki ;
Sung, Kyu-Bo ;
Lim, Young-Suk ;
Lee, Han Chu ;
Chung, Young Hwa ;
Lee, Yung Sang ;
Suh, Dong Jin .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (05) :806-814